Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-22-024653
Filing Date
2022-02-01
Accepted
2022-02-01 16:45:02
Documents
2
Group Members
PABLO G. LEGORRETAROYALTY PHARMA INVESTMENTS 2019 ICAVRP MANAGEMENT, LLC

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d661507dsc13da.htm SC 13D/A 92060
2 EXHIBIT A d661507dex99a.htm EX-99.A 9759
  Complete submission text file 0001193125-22-024653.txt   103454
Mailing Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139 617-229-5872
Epizyme, Inc. (Subject) CIK: 0001571498 (see all company filings)

EIN.: 261349956 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-87481 | Film No.: 22579492
SIC: 2834 Pharmaceutical Preparations

Mailing Address 110 EAST 59TH STREET SUITE 3300 NEW YORK NY 10022
Business Address 110 EAST 59TH STREET SUITE 3300 NEW YORK NY 10022 212-883-0200
RPI Finance Trust (Filed by) CIK: 0001793690 (see all company filings)

EIN.: 456358481 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A